Get the Stockscreener App
1.1202
2.77%
0.0302
After Hours:
1.12
-0.0002
-0.02%
Artelo Biosciences Inc stock is traded at $1.1202, with a volume of 7,101.
It is up +2.77% in the last 24 hours and down -13.83% over the past month.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.
See More
Previous Close:
$1.09
Open:
$1.15
24h Volume:
7,101
Relative Volume:
0.09
Market Cap:
$3.52M
Revenue:
-
Net Income/Loss:
$-9.60M
P/E Ratio:
-0.3374
EPS:
-3.32
Net Cash Flow:
$-8.96M
1W Performance:
+2.77%
1M Performance:
-13.83%
6M Performance:
-24.31%
1Y Performance:
-23.27%
1-Day Range:
$1.0801
$1.15
1-Week Range:
$1.07
$1.16
52-Week Range:
$1.00
$1.78
Artelo Biosciences Inc Stock (ARTL) Company Profile
Name
Artelo Biosciences Inc
Sector
Industry
Phone
858-925-7049
Address
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-21 | Initiated | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc Stock (ARTL) Latest News
Equities Analysts Offer Predictions for Stitch Fix, Inc.’s Q1 2025 Earnings (NASDAQ:SFIX) - Defense World
Anorexia Nervosa Market Expected to Experience Major Growth - openPR
ARTL stock touches 52-week low at $1.12 amid market challenges - Investing.com Canada
ARTL stock touches 52-week low at $1.12 amid market challenges - Investing.com UK
Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference - ForexTV.com
Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
ARTL Stock Earnings: Artelo Biosciences Beats EPS for Q2 2024 - MSN
ARTLW (Artelo Biosciences) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com
ARTL (Artelo Biosciences) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com
ARTL (Artelo Biosciences) EV-to-Revenue : (As of Aug. 17, 2024) - GuruFocus.com
HC Wainwright Weighs in on Artelo Biosciences, Inc.’s Q3 2024 Earnings (NASDAQ:ARTL) - Defense World
Artelo Biosciences’ (ARTL) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Artelo Biosciences (NASDAQ:ARTL) Announces Earnings Results - Defense World
ARTL Stock Earnings: Artelo Biosciences Beats EPS for Q2 2024 - InvestorPlace
Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update - BioSpace
Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update - StockTitan
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Up 3,808.3% in July - Defense World
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Down 91.5% in July - Defense World
New drug to control pain related to cancer treatment originally developed at Stony Brook gets FDA clearance - TBR News Media
UK life sciences can lead the way in global cannabinoid R&D says CRDG report - European Pharmaceutical Manufacturer
Artelo’s FABP5 inhibitor cleared to enter clinic for chemotherapy-induced peripheral neuropathy - BioWorld Online
Artelo Biosciences Inc (ARTL)’s Market Momentum: Closing Strong at 1.33, Up 2.71 - The Dwinnex
FDA greenlights Artelo Biosciences' neuropathy drug trial By Investing.com - Investing.com Nigeria
PSEG sets $0.60 quarterly dividend for Q3 2024 By Investing.com - Investing.com
Artelo Biosciences Inc (ARTL) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
FDA greenlights Artelo Biosciences' neuropathy drug trial By Investing.com - Investing.com Canada
FDA clears Artelo’s FABP5 inhibitor trial - Yahoo Finance
Artelo stock jumps 13% after FDA okays ART26.12 Phase 1 study (NASDAQ:ARTL) - Seeking Alpha
Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor - ForexTV.com
Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor - StockTitan
Pharmacokinetic evaluation of novel cannabidiol formulation presented - BioWorld Online
Artelo Biosciences Presents Data From Preclinical Studies On ART12.11 At 34th Annual International Cannabinoid Research Society Symposium - Quantisnow
Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium - Yahoo Finance
Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium - StockTitan
Artelo Biosciences Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform - StockTitan
Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society Symposium - Quantisnow
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update - Defense World
Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society Symposium - StockTitan
Q4 Investor Summit Small Cap & Micro Cap Conference To Offer Opportunity to Meet with C-level Management of 90 ... - The Globe and Mail
Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors - Quantisnow
Cancer Cachexia Market Report 2034: FDA, EMA, PDMA Approvals, Clinical Trials, Pipeline, Epidemiology, and ... - openPR
Cancer Cachexia Market Report 2034: FDA, EMA, PDMA Approvals, Clinical Trials, Pipeline, Epidemiology, and ... - Barchart
Toni Thompson Nadal Sells 1444 Shares of Etsy, Inc. (NASDAQ:ETSY) Stock - Defense World
Bulldog Investors LLP Increases Position in BNY Mellon Strategic Municipal Bond Fund, Inc. (NYSE:DSM) - Defense World
Artelo Biosciences presents important new data on ART26.12TipRanks.com - TipRanks
Artelo Biosciences' (ARTL) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society - GlobeNewswire Inc.
Artelo reports promising pre-clinical data on ART12.11 - Investing.com India
Artelo reports promising pre-clinical data on ART12.11 By Investing.com - Investing.com
Artelo reports promising pre-clinical data on ART12.11 By Investing.com - Investing.com UK
Artelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT ... - Yahoo Finance
Artelo Biosciences Inc Stock (ARTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):